The phase II SERENA-2 trial (NCT04214288) compared the safety and efficacy of camizestrant (in doses of 75 and 150 mg) with fulvestrant in post-menopausal women with advanced ER+/HER2− BC who progressed after previous ET. Here, ESR1 is linked to breast cancer.